mots-c and retatrutide Body Retatrutide vs SS-31 & MOTS-C:
Description
Lancet Diabetes Endocrinol 2020;8:880-93.ArticlePubMed 115
Retatrutide is a new weight loss treatment that targets multiple hormone pathways related to weight regulation
A retrospective study of patients in the NYU Lupus Cohort found that GLP1-RA use was associated with significantly decreased BMI and did not confer a higher risk of flares, though notably the sample size was small13
Additionally, the data has piled up (anecdotal but in significant volumes) about GLP-1s resulting in less drinking by patients
Policymakers should mandate coverage for GLP-1 products for both diabetes and obesity across public and private payers
